Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04282187
Title Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

myeloproliferative neoplasm

essential thrombocythemia

myelodysplastic/myeloproliferative neoplasm

myelofibrosis

polycythemia vera

Therapies

Decitabine + Fedratinib

Decitabine + Ruxolitinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.